Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
Shuang Zhang et al.
NATURE COMMUNICATIONS (2019)
The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review
Ioannis Ntanasis-Stathopoulos et al.
CANCER INVESTIGATION (2016)
Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy
Kristin Blom et al.
JALA (2016)
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei
Kathrine Bjersand et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Ovarian cancer treatment: The end of empiricism?
Stephanie Lheureux et al.
CANCER (2015)
Oxaliplatin for the treatment of ovarian cancer
Stefano Bogliolo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Role of aggressive surgical cytoreduction in advanced ovarian cancer
Suk-Joon Chang et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2015)
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute
John D. Hainsworth et al.
CANCER MEDICINE (2015)
Chemotherapeutic drug sensitivity of primary cultures of epithelial ovarian cancer cells from patients in relation to tumour characteristics and therapeutic outcome
Anne von Heideman et al.
ACTA ONCOLOGICA (2014)
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
Thomas J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2014)
Epithelial Ovarian Cancer Rationale for Changing the One- Fits- All Standard Treatment Regimen to Subtype- Specific Treatment
Evelyn Despierre et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study
Ignace B. Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
John Farley et al.
LANCET ONCOLOGY (2013)
Recent Progress in the Diagnosis and Treatment of Ovarian Cancer
Danijela Jelovac et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer
Thomas J. Herzog et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2010)
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Robert J. Kurman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Current state of biomarker development for clinical application in epithelial ovarian cancer
Richard G. Moore et al.
GYNECOLOGIC ONCOLOGY (2010)
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2009)
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Kathleen M. Schmeler et al.
GYNECOLOGIC ONCOLOGY (2008)
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei)
Brendan Moran et al.
JOURNAL OF SURGICAL ONCOLOGY (2008)
The fluorometric microculture cytotoxicity assay
Elin Lindhagen et al.
NATURE PROTOCOLS (2008)
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
Ian A. Cree et al.
ANTI-CANCER DRUGS (2007)
Methods and goals for the use of in vitro and in vivo chemosensitivity testing
Rosalyn D. Blumenthal et al.
MOLECULAR BIOTECHNOLOGY (2007)
Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations
T Fojo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma
PA Vasey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Ovarian tumorigenesis - A proposed model based on morphological and molecular genetic analysis
IM Shih et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Ovarian cancer: Strategies for overcoming resistance to chemotherapy
R Agarwal et al.
NATURE REVIEWS CANCER (2003)
Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy
V Loizzi et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2003)
The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer
JB Vermorken
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2001)
Share Paper
